CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS

NCT ID: NCT02543788

Last Updated: 2025-09-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with multiple sclerosis (MS) may show chronic signs of optic neuropathy (CON) that may follow acute optic neuritis (secondary form of CON, S-CON) or occur independently of any acute demyelinating lesion of the optic nerve (primary form of CON, P-CON). In both S-CON and P-CON, a long term progressive ganglion cell axonal loss occurs. This axonal damage could be secondary to retrograde atrophy of axons within plaques of demyelination or a primary progressive degeneration of ganglion cells, but the underlying physiopathology has not been fully questioned in the different profile types of CON.

In this project, investigators aim at understanding the pathophysiology of S-CON and P-CON, i.e. secondary to demyelination or primary degeneration, in patients complaining of persistent visual complaints. In a first cross sectional study, 30 MS patients with mild to moderate P-CPON or S-CON and 30 age-matched control subjects will perform an extensive neuro-ophthalmological assessment including clinical examination, visual evoked potentials (pattern and low contrast), electroretinogram (pattern and multifocal ERG), OCT (peripapillary and macular volume scan segmentation protocols) and MRI of the optic nerve. In these patients with mild to moderate CON, investigators aim at differentiating patients showing predominant demyelination from those showing pure or predominant axonal degeneration. Visual function assessment and degree of axonal degeneration will be compared and correlated in the two types of underlying pathophysiology and in the group of control subject. In a following longitudinal study, the patients will be re-assessed a year later in order to evaluate the progression of CON in both profile types. Our hypothesis would be that visual function and progression is worse in the degeneration group as compared to the demyelination group. This study should help to find reliable measures of the pathophysiology of CON and correlate it with the long-term visual prognostic of the disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Optic Neuropathy in Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients

patients with chronic optic neuropathy in multiple sclerosis

Group Type OTHER

• Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG

Intervention Type PROCEDURE

Controls

healthy volunteers

Group Type OTHER

• Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

• Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients may have a clinically definite, laboratory-supported diagnosis of multiple sclerosis according to the Mac Donald criteria (2010).
* All patients may present a chronic visual complaint.
* All patients may present mild to moderate chronic optic neuropathy (cf infra)
* All patients may not have recent acute optic neuritis (\<2 years)
* All patients will be informed about the design and purpose of the study, and all will give their informed, written consent to the protocol, which may have been approved by the local ethics committee.
* Age: \> 18
* Able to understand the instructions
* Having a health coverage
* Able to sit down for 1 hour Diagnosis of mild to moderate chronic optic neuropathy

For the diagnosis of optic neuropathy, patients will have to meet 3 of the 6 next criteria:

1. Far Visual Acuity (ETDRS charts, 100% contrast) \< 85 letters
2. Far Visual Acuity (ETDRS charts, 2.5% contrast) \< 60 letters
3. Mean visual field defect on static perimetry\> 2dB
4. Mean pRNFL in OCT \< 80 µ.
5. Color vision score \> 35
6. Disc pallor Diagnosis of mild to moderate optic neuropathy

* Far Visual Acuity (ETDRS charts, 100% contrast) \>70 letters Diagnosis of chronic optic neuropathy
* Stable or worsening of visual acuity, visual field and/or RNFL in OCT, at 6 month of interval

* Age \> 18 years
* Visual acuity score (ETDRS) \> 85
* Able to understand the instructions
* Having a health coverage
* Informed and consenting to give his written consent


* Ophthalmological

* Other ophthalmological disorder that could impair corrected visual acuity (Maculopathy, Retinopathy…)
* Ocular instability in primary position of gaze
* Neurological

* Ongoing seizure
* Severe handicap that does not allow sitting down position for 1 hour
* General

* Unstable medical state
* Severe renal insufficiency
* Allergy to gadolinium
* Claustrophobia
* Implanted electrical stimulator (pace maker)
* Metallic prosthesis or orthesis, cochlear implants
* Intraocular foreign material
* Pregnancy (on questioning)
* Tutelage or any legal protection measure

* Any ophthalmological disorder that could impair corrected visual acuity
* Any neurological disorder
* MRI contraindication
* Allergy to gadolinium
* Severe renal insufficiency
* Claustrophobia
* Implanted electrical stimulator (pace maker)
* Metallic prosthesis or orthesis, cochlear implants
* Intraocular foreign material
* Pregnancy (on questioning)
* Tutelage or any legal protection measure
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondation pour la Recherche Médicale

OTHER

Sponsor Role collaborator

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Caroline TILIKETE, MD

Role: PRINCIPAL_INVESTIGATOR

Unité de Neuro-Ophtalmologie - Hôpital Neurologique - HOSPICES CIVILS DE LYON - France

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Unité de Neuro-Ophtalmologie - Hôpital Neurologique - HOSPICES CIVILS DE LYON

France, BRON, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Physiopathologie de la Neuropathie Optique Chronique de la SEP " Lucie ABOUAF, François DURAND-DUBIEF, Sandra VUKUSIC, Alain VIGHETTO, Caroline TILIKETE. Communication orale aux 3e journée des Neurosciences de l'Hôpital Neurologique le jeudi 24 septembre 2015, Institut des Sciences Cognitives, Lyon.

Reference Type BACKGROUND

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014.850

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Fampridine-SR and Optic Neuritis Recovery
NCT04148781 UNKNOWN EARLY_PHASE1